Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
141.7(c) 131.9(c) 131.31(c) 132.55(c) 130.46(c) Last
2 947 097 11 374 611 6 188 028 4 099 914 4 296 423 Volume
-0.48% -6.92% -0.45% +0.94% -1.58% Change
More quotes
Financials (USD)
Sales 2020 23 723 M - -
Net income 2020 6 107 M - -
Net Debt 2020 11 184 M - -
P/E ratio 2020 20,2x
Yield 2020 2,27%
Sales 2021 25 927 M - -
Net income 2021 7 254 M - -
Net Debt 2021 8 770 M - -
P/E ratio 2021 16,5x
Yield 2021 2,50%
Capitalization 120 B 120 B -
EV / Sales 2020 5,54x
EV / Sales 2021 4,97x
Nbr of Employees 33 625
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both... 
Sector
Pharmaceuticals
Calendar
11/04Presentation
More about the company
Notations Surperformance© of Eli Lilly and Company
Trading Rating : Investor Rating :
More Ratings
All news about ELI LILLY AND COMPANY
10:45aELI LILLY AND COMPANY : - New Data at EADV 2020 Confirm Taltz Demonstrates Susta..
AQ
06:46aFALL CLINICAL DERMATOLOGY 2020 : Lilly and Incyte Showcase Positive New Data for..
PR
10/29ELI LILLY AND : US to receive 300,000 vials of experimental COVID-19 antibody th..
AQ
10/29ELI LILLY AND : Lilly announces agreement with U.S. government to supply 300,000..
AQ
10/29ELI LILLY AND COMPANY : - Data for Lilly's bamlanivimab in COVID-19 outpatients ..
AQ
10/29ELI LILLY AND : HHS, DOD Collaborate on Plans to Purchase of Lilly Investigation..
AQ
10/29ELI LILLY AND : New Data at EADV 2020 Confirm Taltzģ (ixekizumab) Demonstrates S..
PR
10/28ELI LILLY AND : Submits New Data on Covid-19 Treatment Drug
DJ
10/28REGENERON PHARMACEUTICALS : says its COVID-19 antibody treatment cut medical vis..
RE
10/28ELI LILLY AND : Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatient..
PR
10/28U.S. Reaches $375 Million Deal for Lilly Covid-19 Antibody Drug
DJ
10/28ELI LILLY AND : & CO Management's Discussion and Analysis of Results of Operatio..
AQ
10/28ELI LILLY AND COMPANY : - Lilly Reports Third-Quarter Financial Results, Updates..
AQ
10/28ELI LILLY AND : Gets Deal With U.S. Government for Covid-19 Neutralizing Antibod..
DJ
10/28ASTRAZENECA : U.S. strikes deal with Lilly for potential COVID-19 antibody drug
RE
More news
News in other languages on ELI LILLY AND COMPANY
10/29Christine, délivre-nous du mal !
10/29EN DIRECT DES MARCHES : LVMH, Airbus, Orange, Sanofi, Faurecia, GTT, Crédit Suis..
10/29Amgen aidée par les ventes d'un médicament contre l'ostéoporose
10/28CORONAVIRUS : Regeneron et Eli Lilly publient des résultats prometteurs
10/28Basilea et Eli Lilly collaborent sur un traitement contre le cancer gastrique
More news
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 165,83 $
Last Close Price 130,46 $
Spread / Highest target 53,3%
Spread / Average Target 27,1%
Spread / Lowest Target -8,02%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY-0.74%120 167
JOHNSON & JOHNSON-5.95%361 159
ROCHE HOLDING AG-6.40%274 461
PFIZER INC.-9.95%196 047
MERCK & CO., INC.-16.56%191 944
NOVARTIS AG-22.62%176 518